Form 8-K

8-K — Cytek Biosciences, Inc.

Accession: 0001193125-26-211948

Filed: 2026-05-07

Period: 2026-05-07

CIK: 0001831915

SIC: 3826 (LABORATORY ANALYTICAL INSTRUMENTS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — d146722d8k.htm (Primary)

EX-99.1 (d146722dex991.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d146722d8k.htm · Sequence: 1

8-K

false 0001831915 0001831915 2026-05-07 2026-05-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 7, 2026

Cytek Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-40632

47-2547526

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

47215 Lakeview Boulevard

Fremont, California

94538

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (877) 922-9835

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.001 per share

CTKB

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations and Financial Condition.

On May 7, 2026, Cytek Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. The press release is being furnished as Exhibit 99.1.

The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description of Exhibit

99.1

Press release dated May 7, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cytek Biosciences, Inc.

Date: May 7, 2026

By:

/s/ Wenbin Jiang

Wenbin Jiang, Ph.D.

President and Chief Executive Officer

EX-99.1

Filename: d146722dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Cytek Biosciences Reports First Quarter 2026 Financial Results

FREMONT, Calif., May 7, 2026 (GLOBE NEWSWIRE) – Cytek Biosciences, Inc. (“Cytek Biosciences” or

“Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2026.

Recent Highlights

•

Total revenue for the first quarter of 2026 was $44.1 million, representing a 6% increase compared to the

first quarter of 2025

•

Service revenue for the first quarter of 2026 was $15.4 million, representing a 15% increase compared to the

first quarter of 2025

•

Total recurring revenue, comprised of service and reagent revenues, reached $18.4 million in the first

quarter. On a trailing-12-month basis, recurring revenue represented 35% of total revenue, up from 31% on a trailing-12-month basis as of the first quarter of 2025

•

Expanded to a total installed base of 3,789 Cytek instruments, adding 125 units in the first quarter of 2026

“Our first quarter growth stands out in a market that continues to experience global challenges, underscoring Cytek’s

technology leadership, the growth of our installed base, and the expansion of our recurring revenue streams,” said Wenbin Jiang, CEO of Cytek Biosciences. “Rising instrument placements are expanding our installed base and driving higher

demand for reagents and service, making recurring revenue an increasing share of total revenue. With focused execution and continued investment in our products, people, and infrastructure, we are well positioned for the year ahead.”

First Quarter 2026 Financial Results

Total revenue for

the first quarter of 2026 was $44.1 million, a 6% increase compared to the first quarter of 2025. The increase in revenue was driven by strong revenue performance in the US and continued growth in service and reagent revenue worldwide.

GAAP gross profit was $21.3 million for the first quarter of 2026, a 5% increase compared to the first quarter of 2025. GAAP gross profit margin was 48%

in the first quarter of 2026 compared to 49% in the first quarter of 2025. Adjusted gross profit margin, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles, was 51% in the first quarter of 2026

compared to 52% in the first quarter of 2025.

Operating expenses were $39.7 million for the first quarter of 2026, a 13% increase compared to the

first quarter of 2025 due to increased general and administrative expenses, partially offset by a reduction in sales and marketing and research and development expenses.

Research and development expenses were $9.6 million for the first quarter of 2026, a 1% decrease compared to the first quarter of 2025.

Sales and marketing expenses were $11.6 million for the first quarter of 2026, a 7% decrease compared to the first quarter of 2025.

General and administrative expenses were $18.5 million for the first quarter of 2026, increasing 43%

compared to the first quarter of 2025 due primarily to litigation-related expenses, outside consulting expenses and bad debt reserves.

Loss from

operations in the first quarter of 2026 was $18.5 million compared to loss from operations of $15.0 million in the first quarter of 2025. Net loss in the first quarter of 2026 was $18.9 million compared to a net loss of

$11.4 million in the first quarter of 2025.

Adjusted EBITDA loss in the first quarter of 2026 was $9.1 million compared to an adjusted EBITDA

loss of $3.3 million in the first quarter of 2025, after adjusting for stock-based compensation expense and foreign currency exchange impacts.

Cash

and marketable securities totaled $262.2 million as of March 31, 2026 compared to $261.5 million as of December 31, 2025, an increase of $0.7 million.

2026 Outlook

Cytek Biosciences reaffirms its 2026

revenue guidance to be in the range of $205 million to $212 million, representing growth of 2% to 5% over full year 2025, assuming no change from current currency exchange rates.

Webcast Information

Cytek will host a conference call to

discuss its first quarter 2026 financial results on Thursday, May 7, 2026, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the conference call can be accessed at investors.cytekbio.com.

About Cytek Biosciences, Inc.

Cytek Biosciences (Nasdaq:

CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information

within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek

Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the

Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions

for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern

Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek

Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference

calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and

industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website,

LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Statement Regarding Use of

Non-GAAP Financial Information

Cytek has presented certain financial information in accordance with generally

accepted accounting principles in the United States (“U.S. GAAP”) and also on a non-GAAP basis for the three-month period ended March 31, 2026 and March 31, 2025. Management believes that

non-GAAP financial measures, including “Adjusted gross profit,” “Adjusted gross profit margin,” and “Adjusted EBITDA loss,” referenced in this release, taken in conjunction

with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating

results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Cytek

encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business.

Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.

Forward-Looking Statements

This press release contains

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as

amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of

forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,”

“target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or

similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, without limitation, statements regarding Cytek’s expanding installed base and future recurring

revenue growth in its service and reagent businesses; Cytek’s business strategy and continued investment in its products, people, and infrastructure; Cytek’s market opportunities; and Cytek’s future financial performance, including

its outlook for fiscal year 2026 and expectations for 2026 total revenue. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also

deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking

statements. In addition, new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements. Factors that could cause actual results

to differ materially include global geopolitical, economic and market conditions; Cytek’s ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business;

Cytek’s ability to evaluate its prospects for future viability and predict future performance; Cytek’s ability to accurately forecast customer demand and adoption of its products; Cytek’s ability to recognize the anticipated

benefits of collaborations; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its

organization, maintain relationships

with customers and suppliers and hire and retain key employees; Cytek’s ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet

demand; Cytek’s ability to increase penetration in its existing markets and expand into adjacent markets; Cytek’s ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek’s

ability to successfully develop and introduce new products; Cytek’s ability to maintain, protect and enhance its intellectual property; Cytek’s ability to continue to stay in compliance with its material contractual obligations,

applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section titled “Risk Factors” set forth in Cytek’s most recent Annual Report on Form 10-K filed

with the SEC on February 26, 2026, Cytek’s Quarterly Report on Form 10-Q to be filed with the SEC on or about the date hereof and other filings Cytek makes with the SEC from time to time for a

discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements

are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements

will be achieved or occur. The forward-looking statements in this press release and the related conference call, webcast and presentation are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update

any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be

relied upon as representing Cytek’s views as of any date subsequent to the date of this press release. Information contained on, or that is referenced or can be accessed through, our website does not constitute part of this document and

inclusions of any website addresses herein are inactive textual references only.

Media Contact:

Stephanie Olsen

Lages & Associates

(949) 453-8080

stephanie@lages.com

Investor Contact:

Paul Goodson

Head of Investor Relations

Cytek Biosciences

pgoodson@cytekbio.com

Cytek Biosciences, Inc.

Consolidated Balance Sheets

(Unaudited)

(In thousands, except share and per share data)

March 31,

2026

December 31,

2025

Assets

Current assets:

Cash and cash equivalents

65,665

90,853

Marketable securities

196,560

170,676

Trade accounts receivable, net

51,903

62,509

Inventories

49,791

48,428

Prepaid expenses and other current assets

15,383

19,530

Total current assets

379,302

391,996

Property and equipment, net

20,469

18,009

Operating lease

right-of-use assets

10,643

11,315

Goodwill

16,689

16,697

Intangible assets, net

15,704

16,821

Other noncurrent assets

6,306

6,704

Total assets

449,113

461,542

Liabilities and stockholders’ equity

Current liabilities:

Trade accounts payable

6,741

6,410

Legal settlement liability, current

2,208

2,495

Accrued expenses

19,781

23,417

Other current liabilities

22,173

16,978

Deferred revenue, current

30,032

28,504

Total current liabilities

80,935

77,804

Legal settlement liability, noncurrent

6,637

6,786

Deferred revenue, noncurrent

17,672

18,339

Operating lease liability, noncurrent

13,441

14,042

Long-term debt

386

525

Other noncurrent liabilities

2,398

2,307

Total liabilities

121,469

119,803

Stockholders’ equity:

Common stock, $0.001 par value; 1,000,000,000 authorized shares as of March 31, 2026 and

December 31, 2025, respectively; 129,142,587 and 128,550,136 issued and outstanding shares as of March 31, 2026 and December 31, 2025, respectively

129

Additional paid-in capital

445,750

441,107

Accumulated deficit

(120,604

)

(101,738

)

Accumulated other comprehensive gain

2,369

2,241

Total stockholders’ equity

327,644

341,739

Total liabilities and stockholders’ equity

449,113

461,542

Cytek Biosciences, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

Three months ended March 31,

(In thousands, except share and per share data)

2026

2025

Revenue, net:

Product

28,779

28,110

Service

15,356

13,347

Total revenue, net

44,135

41,457

Cost of sales:

Product

15,921

15,529

Service

6,960

5,771

Total cost of sales

22,881

21,300

Gross profit

21,254

20,157

Operating expenses:

Research and development

9,604

9,725

Sales and marketing

11,646

12,509

General and administrative

18,467

12,898

Total operating expenses

39,717

35,132

Loss from operations

(18,463

)

(14,975

)

Other income (expense):

Interest expense

(262

)

(291

)

Interest income

787

508

Other income, net

565

3,492

Total other income, net

1,090

3,709

Loss before income taxes

(17,373

)

(11,266

)

Provision for income taxes

1,493

136

Net loss

(18,866

)

(11,402

)

Net loss, basic and diluted

(18,866

)

(11,402

)

Net loss per share, basic

(0.15

)

(0.09

)

Net loss per share, diluted

(0.15

)

(0.09

)

Weighted-average shares used in calculating net loss per share, basic

128,704,934

128,339,481

Weighted-average shares used in calculating net loss per share, diluted

128,704,934

128,339,481

Comprehensive loss:

Net loss

(18,866

)

(11,402

)

Foreign currency translation adjustment, net of tax

328

(560

)

Unrealized loss on marketable securities

(201

)

(65

)

Net comprehensive loss

(18,739

)

(12,027

)

Cytek Biosciences, Inc.

Reconciliation of GAAP to Non-GAAP Measures

(Unaudited)

Three months ended

(In thousands)

March 31, 2026

March 31, 2025

(Unaudited)

GAAP gross profit

21,254

20,157

Stock based compensation

729

1,086

Amortization of acquisition-related intangible assets

494

493

Non-GAAP adjusted gross profit

22,477

21,736

GAAP gross margin

Non-GAAP adjusted gross margin

GAAP net income

(18,866

)

(11,402

)

Depreciation and amortization

2,812

2,881

Provision for (benefit from) income taxes

1,493

136

Interest income

(787

)

(508

)

Interest expense

262

291

Foreign currency exchange loss (gain)

1,152

(1,278

)

Stock based compensation

4,861

6,629

Non-GAAP adjusted EBITDA

(9,073

)

(3,251

)

Investment income

(1,629

)

(2,261

)

Non-GAAP adjusted EBITDA excluding investment

income

(10,702

)

(5,512

)

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Document and Entity Information

May 07, 2026

Cover [Abstract]

Amendment Flag

false

Entity Central Index Key

0001831915

Document Type

8-K

Document Period End Date

May 07, 2026

Entity Registrant Name

Cytek Biosciences, Inc.

Entity Incorporation State Country Code

Entity File Number

001-40632

Entity Tax Identification Number

47-2547526

Entity Address, Address Line One

47215 Lakeview Boulevard

Entity Address, City or Town

Fremont

Entity Address, State or Province

Entity Address, Postal Zip Code

94538

City Area Code

(877)

Local Phone Number

922-9835

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common Stock, par value $0.001 per share

Trading Symbol

CTKB

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration